Selecting a Favorable KIR Donor in Unrelated HCT for AML
Acute Myelogenous Leukemia
About this trial
This is an interventional treatment trial for Acute Myelogenous Leukemia focused on measuring acute myelogenous leukemia, hematopoietic cell transplantation, unrelated donor
Eligibility Criteria
Inclusion Criteria:
- Patient with acute myeloid leukemia (AML) undergoing screening for potential URD HCT
- Potential URD undergoing screening to provide a HCT graft to a patient with acute myeloid leukemia (AML) at a participating institution
- Provides written consent
Exclusion Criteria:
Transplant Centers will select the best HLA matched, and as appropriate, preferred KIR donor. In situations where the preferred (best > better > neutral) KIR donor is not selected in favor of a less favorable KIR genotype donor, the center will report one or more defined reasons (donor age; gender; parity; CMV status; ABO status; availability/logistics; other) for the choice (among equivalently HLA matched donors).
Sites / Locations
- Mayo Clinic - Scottsdale
- Colorado Blood Cancer Institute
- Emory University
- University of Chicago Medical Center Cancer Center
- Indiana University Simon Cancer Center
- Kansas University Cancer Center
- Masonic Cancer Center, University of Minnesota
- Mayo Clinic Cancer Center
- Washington University School of Medicine
- Hackensack University Medical Center
- Roswell Park Cancer Institute
- New York Presbyterian Weill Cornell Medical Center
- Cleveland Clinic
- Ohio State University Comprehensive Cancer Center
- University of Pennsylvania
- Baylor Sammons Cancer Center
- M.D. Anderson Cancer Center
- Methodist Healthcare System of San Antonio
- Fred Hutchinson Cancer Research Center
Arms of the Study
Arm 1
Experimental
Unrelated Donor Transplant Patients
Patients with acute myeloid leukemia who have received KIR genotype from an unrelated donor transplant.